Jazz Pharmaceuticals (JAZZ) opened 2026 with Q1 revenue of US$1.1 billion and basic EPS of US$4.74, setting a clear marker against last year’s volatile run of quarterly results. Over recent quarters the company has seen revenue move from US$897.8 million in Q1 2025 to US$1.09 billion in Q4 2024 and then to US$1.07 billion in Q4 2025. Basic EPS has shifted from a loss of US$1.52 per share in Q1 2025 to US$3.16 in Q4 2024 and US$3.33 in Q4 2025, leaving investors focused on how much of the latest quarter’s profitability will stick as margins settle.

See our full analysis for Jazz Pharmaceuticals.

With the headline numbers on the table, the next step is to set these results against the widely followed narratives around Jazz’s growth profile, risk factors and long term margin potential to see which stories hold up and which need a rethink.

Trailing profit margin stuck at 0.7% after US$1.5b one off

• Over the last twelve months Jazz generated US$4.4b of revenue and US$29.5 million of net income, which works out to a 0.7% net margin compared with 11.9% a year earlier, even though individual quarters like Q1 2026 showed net income of US$293.1 million.
• Bears argue that pressure on margins and earnings quality will hang over the story, and the trailing margin and one off loss give them clear talking points.
  • Critics highlight that trailing basic EPS sits at US$0.48 even with solid quarterly EPS prints, after a one off loss of US$1.5b pulled twelve month earnings down.
  • At the same time, five year earnings grew around 6% per year in the data, so the very low 0.7% margin reflects recent charges rather than longer run profitability alone.

Over the last year, skeptics point to the large one off loss and thin trailing margin as reasons to question how durable recent profit is, and they warn that acquisition related charges and debt costs could keep returns uneven even when headline EPS looks strong. 🐻 Jazz Pharmaceuticals Bear Case

Q1 profit rebound vs loss filled trailing year

• Q1 2026 net income of US$293.1 million contrasts with a twelve month net income of US$29.5 million, showing how heavily the US$1.5b one off loss weighed on the full year figure even as more recent quarters reported positive earnings.
• The bullish narrative leans on that rebound in quarterly profitability to support a view that earnings power is stronger than the trailing twelve month figures suggest.
  • Supporters point out that Q1 2026 basic EPS of US$4.74 and Q3 and Q4 2025 EPS above US$3 came after the quarter with a loss of US$718.5 million in Q2 2025, so recent results line up more with the profitable periods than with the loss making one.
  • Bulls also reference five year earnings growth of about 6% per year in the data and argue that the large loss is a single period event rather than a sign that the business cannot generate profit across a full cycle.

Bulls argue that when you look past the quarter hit by the US$1.5b loss, the recent run of EPS numbers paints a very different picture of earnings power and helps explain why some investors focus on forward profit rather than the depressed trailing average. 🐂 Jazz Pharmaceuticals Bull Case

P/S discount and DCF gap catch the eye

• The stock trades on a P/S of 3.2x against peer and US Pharmaceuticals industry averages of 4.3x and 5.5x, and the latest DCF fair value in the data is US$808.36 per share versus a current price of US$228.57, which is reported as about 71.7% below that DCF number.
• Consensus narrative suggests the mix of new launches and portfolio expansion could support that valuation gap, but the current earnings profile gives both sides of the debate numbers to point to.
  • On one hand, analysts in the supplied data expect revenue to grow around 7.1% per year and earnings to grow around 28.6% per year over the next three years, which many bulls see as consistent with a discount to the US Pharmaceuticals P/E of 15.8x and to the DCF fair value.
  • On the other hand, the same data flags high debt and recent insider selling, along with the 0.7% trailing net margin, as factors that could justify at least part of the P/S and DCF gap if future results fall short of those earnings growth expectations.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Jazz Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed messages in the data or a clear opportunity waiting to be tested; either way, it pays to look under the hood yourself and weigh both the risks and upsides the company is facing, starting with 3 key rewards and 4 important warning signs.

See What Else Is Out There

The trailing 0.7% net margin, US$1.5b one off loss and high debt in the data all raise questions about consistency and financial resilience.

If that mix of thin margins and balance sheet pressure feels uncomfortable, act on it today by comparing options in the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.